Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab

被引：12

作者：

Fogarty, GB ^{[1
]}

Bayne, M

Bedford, P

Bond, R

Kannourakis, G

机构：

[1] Mater Hosp, Sydney, NSW, Australia

[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] St John God Hosp, Ballarat, Australia

[4] Ballarat Oncol Serv, Ballarat, Australia

来源：

CLINICAL ONCOLOGY | 2006年 / 18卷 / 02期

关键词：

D O I：

10.1016/j.clon.2005.11.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：155 / 156

页数：2

共 7 条

[1] Delayed-onset neutropenia associated with rituximab therapy [J].

Chaiwatanatorn, K ;

Lee, N ;

Grigg, A ;

Filshie, R ;

Firkin, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) :913-918

[2]

Grillo-Lopez Antonio J, 2003, Expert Rev Anticancer Ther, V3, P767, DOI 10.1586/14737140.3.6.767

[3] Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function? [J].

Hemminki, K ;

Jiang, Y ;

Steineck, G .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (02) :223-229

[4] Rituximab: Mechanism of action and resistance [J].

Maloney, DG ;

Smith, B ;

Rose, A .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :2-9

[5]

Singh R, 2005, CURR OPIN RHEUMATOL, V17, P274

[6]

Tsutsumi Yutaka, 2005, Expert Opin Drug Saf, V4, P599, DOI 10.1517/14740338.4.3.599

[7] Rituximab (Mabthera™, Rituxan™) in patients with recurrent indolent lymphoma -: Evaluation of safety and efficacy in a multicenter study [J].

Walewski, J ;

Kraszewska, E ;

Mioduszewska, O ;

Romejko-Jarosinska, J ;

Hellmann, A ;

Czyz, J ;

Holowiecki, J ;

Kopera, M ;

Grosicki, S ;

Komarnicki, M ;

Rumianowski, L ;

Kuliczkowski, K ;

Wróbel, T ;

Dwilewicz-Trojaczek, J ;

Robak, T ;

Warzocha, K ;

Zaluski, J ;

Wójcik, E ;

Dmoszynska, A ;

Walter-Croneck, A .

MEDICAL ONCOLOGY, 2001, 18 (02) :141-148

← 1 →